Insmed stock
INSMNASDAQInsmed Incorporated, HealthcareISIN US4576693075
43Score 43 out of 100, Weak
Price and trend
57 / 100
Price history
−39% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 4.3% below it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 75).
The price is 44% below its 52-week high. Largest decline in 20 years: 89% (June 2009 to November 2011).
Chart figures for advanced users
- SMA 50$110.93
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$123.35
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$91.88
- The lowest closing price of the last twelve months.
- Resistance$211.41
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Insmed Incorporated belongs to the Biotechnology industry (United States) and, with a market value of $25.9B, is number 13 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $606.42M (up 66.7% year on year) and a loss of $1.28B.
- For fiscal 2026, analysts expect on average revenue of $1.86B (up 206.3%) and adjusted earnings per share of −$1.64.
Show more
- MEQIRI Score 43 out of 100 (Weak): rank 488 of 702 in Healthcare, median 53.
- Our model puts fair value at $212.56, with the price 44% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 29.8% a year since 2020, Biotechnology median 19.4%.Growth 70
- More cash than debtCash $1.15B, financial debt $741.17M.
Weaknesses
- DilutionShare count up 119% since 2020.Capital allocation 18
- Loss-makingLoss of $605.61M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$657.58M over the last 12 months.Fundamentals 17
Its standout strengths are valuation and growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 23 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- weak fundamentals
- price far below its 52-week high
- high price swings
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $141.71 and expensive above $425.12 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $178.25, at 8.3% it would be $262.19.
Possible value trap: looks cheap, but score below 50, weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 240% on the twelve months before. Revenue has grown strongly since 2018, at around 80% per year. From 2018 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 79%, operating −194%, net −211%. Last 12 months: net −40%. From 2018 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Feb 2027in 97 days
- Last reported
- 29 Oct 2026EPS reported −$0.46 (expected −$0.38)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 7.3% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$1.64−2.7%
- Revenue
- $1.86B+3.5%
- Earnings per share
- $0.70−7.3%
- Revenue
- $2.99B+2.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +16.1%Insmed raised its full year 2026 guidance for BRINSUPRI revenue to $1.35 billion to $1.4 billion and for ARIKAYCE revenue to $460 million to $470 million, both increases versus the prior ranges.
“Given BRINSUPRI's consistent outperformance to date, we are raising our full-year 2026 revenue guidance range to $1.35 billion-$1.4 billion, which represents an increase to the low end of our previous guidance range by $100 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $52.5M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Brennan David RSale
9 Sept 2026, Board
- Shares
- 25,000
- Price
- $124.00
- Value
- $3.1M
- Sharoky Melvin MdSale
17 Aug 2026, Board
- Shares
- 5,000
- Price
- $127.53
- Value
- $637,650
- Adsett RogerSale
10 Aug 2026, Chief Operating Officer
- Shares
- 239,850
- Price
- $133.27
- Value
- $31.96M
Show 16 more
- Flammer Martina M.D.Sale
6 Aug 2026, Chief Medical Officer
- Shares
- 27,173
- Price
- $128.61
- Value
- $3.49M
- Lewis WilliamSale
23 Jul 2026, Chair and CEO
- Shares
- 10,700
- Price
- $106.06
- Value
- $1.13M
- Lewis WilliamSale
9 Jul 2026, Chair and CEO
- Shares
- 10,699
- Price
- $117.40
- Value
- $1.26M
- Flammer Martina M.D.Sale
6 Jul 2026, Chief Medical Officer
- Shares
- 12,302
- Price
- $109.98
- Value
- $1.35M
- Lewis WilliamSale
25 Jun 2026, Chair and CEO
- Shares
- 21,398
- Price
- $103.32
- Value
- $2.21M
- Smith Michael AlexanderSale
22 Jun 2026, Chief Legal Officer
- Shares
- 1,806
- Price
- $95.82
- Value
- $173,051
- Lewis WilliamSale
8 Jun 2026, Chair and CEO
- Shares
- 6,515
- Price
- $94.03
- Value
- $612,605
- Flammer Martina M.D.Sale
5 Jun 2026, Chief Medical Officer
- Shares
- 1,858
- Price
- $103.78
- Value
- $192,823
- Adsett RogerSale
3 Jun 2026, Chief Operating Officer
- Shares
- 2,370
- Price
- $102.27
- Value
- $242,380
- Bonstein SaraSale
3 Jun 2026, Chief Financial Officer
- Shares
- 2,404
- Price
- $102.27
- Value
- $245,857
- Smith Michael AlexanderSale
3 Jun 2026, Chief Legal Officer
- Shares
- 2,159
- Price
- $102.27
- Value
- $220,801
- Lewis WilliamSale
3 Jun 2026, Chair and CEO
- Shares
- 7,605
- Price
- $102.27
- Value
- $777,763
- Flammer Martina M.D.Sale
3 Jun 2026, Chief Medical Officer
- Shares
- 2,566
- Price
- $102.27
- Value
- $262,425
- Smith Michael AlexanderSale
22 May 2026, Chief Legal Officer
- Shares
- 6,149
- Price
- $108.47
- Value
- $666,982
- Lewis WilliamSale
18 May 2026, Chair and CEO
- Shares
- 25,564
- Price
- $106.33
- Value
- $2.72M
- Flammer Martina M.D.Sale
14 May 2026, Chief Medical Officer
- Shares
- 10,479
- Price
- $117.54
- Value
- $1.23M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Insmed
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Revolution MedicinesRVMD $38.14B41
- Celltrion068270.KS $35.82B64
- GenmabGMAB.CO $32.18B66
- Roivant SciencesROIV $28.98B48
- WuXi Biologics (Cayman)2269.HK $25.32B73
- United TherapeuticsUTHR $25.27B81
- IncyteINCY $24.81B70
- Alnylam PharmaceuticalsALNY $20.98B57
ETFs that hold Insmed
Held by 67 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 4.13% | 0.89% | €11.72M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 1.56% | 0.35% | €1.25B |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.37% | 0.12% | €1.39B |
Show 5 more
| iShares MSCI USA Mid-Cap Equal Weight UCITS ETFQDVC | 0.36% | 0.20% | €272.21M |
| Deka MSCI USA MC UCITS ETFEL41 | 0.30% | 0.30% | €52.63M |
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 0.25% | 0.25% | €4.12B |
| iShares MSCI World Mid-Cap Equal Weight UCITS ETF USDIS3T | 0.13% | 0.30% | €411.06M |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 0.11% | 0.18% | €839.61M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 14 Feb 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.